科技部新聞稿

科技部與國際生醫加速器扶植新冠病毒防疫尖兵！

 日期：109年4月27日

發稿單位：產學及園區業務司

聯絡人：林明徹科長

電話: 02-2737-7212

E-mail：miclin@nstc.gov.tw

    科技部於去年(108)年底引進波士頓國際生醫加速器SmartLabs來臺，並啟動「SmartLabs全球啟動計畫」，開始進行新創團隊的輔導培訓。SmartLabs是專注於生醫領域的加速器，曾協助新創公司接獲國際大廠訂單(例如：拜耳公司、羅氏大藥廠)，協助生醫領域公司募資超過70億美金，並培育出世界知名的基因編輯公司，包含：Editas Medicine (EDIT)以及CRISPR Therapeutics (CRSP)。

    為了面對全球延燒的新冠肺炎疫情，Smart Labs除了新創團隊的輔導培訓之外，也積極協助國內創新科技防疫在美國的場域驗證以及通過美國FDA 緊急授權(Emergency Use Authorization, EUA)。由長庚大學技轉成立的霍克生技公司，其研發產品是針對病原核酸及蛋白的檢測箱，以及結合試紙檢測方式的手持式快篩儀器。此兩種方式都能應用於COVID-19 病毒的檢測，快篩儀器目前已可達到每機台於一小時內完成300個核酸檢測，預期可運用到偏鄉和無法設置醫療檢測實驗室的地方。

    中正大學技轉成立的奈捷生技公司，以特有之專利技術研發成果應用於醫療診斷的光感測檢測儀器及光感測生物微流體晶片，可將檢測時間從3小時大幅縮短到數分鐘，提供市場精準、即時且低檢體量之即時診斷裝置。奈捷生技也通過科技部科學園區審議會，預計今年將進駐研發基地於新竹科學園區，目前正積極開發新型冠狀病毒COVID-19的醫療檢測平台。

科技部將與SmartLabs一起攜手合作，優先加速防疫產品的商品化以及通過美國FDA 緊急授權，進入國際市場，並成為全球的防疫尖兵！

Press release

April 27, 2020

MOST and SmartLabs cooperate together to fight COVID-19! 

The Ministry of Science and Technology (MOST) cooperates with SmartLabs to kick-off the “SmartLabs Global Launch” program. SmartLabs is an international biomedical accelerator based on the Taiwan Hsinchu Biomedical Science Park.  SmartLabs has helped their client companies partnering with big pharmas, such as Roche Pharma and Bayer, and raised over 7 billion US dollars.  Editas Medicine (EDIT) and CRISPR Therapeutics (CRSP), the two world eminent gene editing companies, are among those startup companies cultivated by SmartLabs.  

     In combating the global COVID-19 outbreak, along with the “SmartLabs Global Launch” program, SmartLabs will conduct mentoring programs for the biomedical start-ups and accelerate the clinical validation and US FDA EUA approval for Taiwanese COVID-19 epidemic prevention products. 

Hawk Scientific Co. from Chang Gung University designed its qPCR nucleic acid detection technology as the portable diagnostic suitcase and the handheld IoT reader with lateral flow strip tests for emerging pathogen outbreaks and animal diseases for on-site detection.  At present, their machines can complete 300 nucleic acid tests within one hour.  Both of their detection systems can be applied in rapid testing of COVID-19 virus.  And the diagnostic systems are intended to use in rural areas where there is no testing laboratory available nearby.

Instant Nanobiosensor Co. (INB), a startup company from National Chung Cheng University, uses its state-of-the-art patented technology to develop a biomarker light sensing chip and analyzer.  It’s a portable, instant, accurate and specimens-saving diagnostic system. Using the system, the reaction time has been drastically reduced from 3 hours to few minutes.  INB has been got the approval by the MOST Science Park Committee to establish a new manufacture facility in Hsinchu Science Park this year and currently the team is developing a COVID-19 diagnostic system for rapid testing.

The MOST will work together with SmartLabs to speed up the commercialization of Taiwanese COVID-19 medical products and to get the approval of US FDA EUA.  With this partnership, “Taiwan’s technologies can help” will be further demonstrated in fighting this global pandemic!

Media Contact

Min-Cheh Lin

Section Chief

Department of Academia-Industry Collaboration and Science Park Affairs,

Ministry of Science and Technology (MOST)

Tel : 886-2-2737-7212

E-mail: miclin@nstc.gov.tw